CARTHERAbioparc - 60 avenue Rockefeller - 69008 LYON
Telephone n°1 : +33 (0)4 72 62 62 71
Telephone n°2 : +33 (0)1 57 27 47 17
CarThera designs and develops innovative therapeutic ultrasound-based medical devices for treating brain disorders. The company is a spin-off from AP-HP and UPMC. CarThera leverages the inventions of Professor Alexandre Carpentier, a neurosurgeon at AP-HP who has achieved worldwide recognition for his innovative developments for treating brain disorders. CarThera developed the SonoCloud®, an intracranial ultrasound implant that temporarily opens the blood-brain barrier (BBB). By increasing the permeability of the cerebral blood vessels using low intensity pulsed ultrasound, the concentration of therapeutic molecules that reach the brain can be increased by five to seven times, with no increase in dose or toxicity. Clinical trials are underway in glioblastoma and in Alzheimer’s disease. CarThera is based at the Brain and Spine Institute (ICM) in Paris, France, and has laboratories at the Bioparc Laënnec business incubator in Lyon, France. The company, led by Frederic Sottilini (CEO), works closely with the Laboratory of Therapeutic Applications of Ultrasound (LabTAU, INSERM) in Lyon. Since its inception, the company has received support from France’s Ministry of Research, the Ile-de-France region, the Bpifrance public investment bank, Medicen and Lyonbiopôle.